Organon & Co. (OGN) Key Metrics
OGN valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $3.61B
- Enterprise value
- $11.03B
- P/E (TTM)
- 17.6 10-yr median 5.7
- Forward P/E
- 5.1
- PEG ratio
- —
- Price / sales
- 0.6 10-yr median 0.6
- Price / book
- 3.6
- EV / EBITDA
- 8.4 10-yr median 8.2
- Dividend yield
- 0.58% $0.08 a year
- Beta
- 1.54
OGN key metrics, 2017–2025
Fiscal year ended December 31, 2025 · U.S. dollarsOGN valuation Price multiples at each fiscal year-end price.
OGN returns How much profit the business earns on the capital it uses.
OGN per-share figures Results divided by the shares outstanding at year-end.
OGN financial health Debt, liquidity and how easily interest is covered.
OGN efficiency & capital use Working capital cycle and where the cash goes.
OGN valuation history
OGN returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
OGN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
OGN cash returned to shareholders
OGN price vs earnings per share
OGN key metrics
2017–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Valuation | |||||||||
| Market capitalization | $1.87B | $3.87B | $3.70B | $7.13B | $7.72B | — | — | — | — |
| Enterprise value | $10.10B | $12.23B | $11.93B | $15.53B | $16.35B | — | — | — | — |
| P/E ratio | 10.0 | 4.5 | 3.6 | 7.8 | 5.7 | — | — | — | — |
| Price / sales | 0.3 | 0.6 | 0.6 | 1.2 | 1.2 | — | — | — | — |
| Price / book | 2.5 | 8.2 | — | — | — | — | — | — | — |
| Price / free cash flow | 3.5 | 6.6 | 6.9 | 16.5 | 3.9 | — | — | — | — |
| Price / operating cash flow | 2.7 | 4.1 | 4.6 | 8.3 | 3.1 | — | — | — | — |
| EV / sales | 1.6 | 1.9 | 1.9 | 2.5 | 2.6 | — | — | — | — |
| EV / EBITDA | 7.8 | 7.6 | 8.3 | 8.8 | 8.2 | — | — | — | — |
| EV / free cash flow | 18.8 | 20.8 | 22.2 | 36.0 | 8.3 | — | — | — | — |
| Earnings yield | 10.0% | 22.3% | 27.7% | 12.9% | 17.5% | — | — | — | — |
| Free cash flow yield | 28.8% | 15.2% | 14.6% | 6.0% | 25.5% | — | — | — | — |
| Dividend yield | 4.7% | 7.7% | 8.0% | 4.1% | 1.9% | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 4.7% | 8.3% | 8.4% | 4.2% | 1.9% | — | — | — | — |
| Share price at fiscal year-end | $7.17 | $14.92 | $14.42 | $27.93 | $30.45 | — | — | — | — |
| Per share | |||||||||
| Revenue per share | $23.84 | $24.71 | $24.44 | $24.20 | $24.86 | $25.77 | $30.72 | $38.62 | $41.48 |
| Earnings per share | $0.72 | $3.33 | $3.99 | $3.59 | $5.33 | $8.52 | $12.71 | $8.51 | $7.11 |
| Operating cash flow per share | $2.68 | $3.62 | $3.12 | $3.36 | $9.69 | $8.63 | $10.93 | $14.57 | $13.51 |
| Free cash flow per share | $2.06 | $2.27 | $2.10 | $1.69 | $7.77 | $7.53 | $10.57 | $14.17 | $13.17 |
| Cash per share | $2.20 | $2.60 | $2.70 | $2.77 | $2.91 | $0.05 | $1.26 | $0.96 | — |
| Book value per share | $2.88 | $1.82 | −$0.27 | −$3.50 | −$5.95 | $21.64 | $27.79 | $25.08 | — |
| Tangible book value per share | −$17.38 | −$21.69 | −$20.31 | −$24.08 | −$26.67 | $1.50 | $7.36 | $3.69 | — |
| Dividends per share | $0.34 | $1.15 | $1.15 | $1.14 | $0.57 | $0.57 | $0.57 | $0.57 | — |
| Capex per share | $0.62 | $1.35 | $1.02 | $1.67 | $1.92 | $1.10 | $0.36 | $0.40 | $0.34 |
| Debt per share | $33.75 | $34.87 | $34.85 | $35.71 | $36.93 | $0.12 | $0.73 | $0.59 | — |
| Shares outstanding | 260.8M | 259.2M | 256.3M | 255.2M | 253.6M | 253.5M | 253.1M | 253.1M | 253.1M |
| Change in shares outstanding | +0.6% | +1.1% | +0.4% | +0.6% | +0.0% | +0.2% | 0.0% | 0.0% | — |
| Returns & profitability | |||||||||
| Return on equity (ROE) | 30.6% | 429.9% | — | — | — | 34.5% | 48.1% | 33.9% | — |
| Return on invested capital (ROIC) | 7.2% | 17.5% | 16.9% | 19.0% | 26.8% | 37.6% | 52.3% | 34.1% | — |
| Return on assets (ROA) | 1.4% | 6.9% | 8.9% | 8.5% | 13.0% | 20.9% | 30.6% | 20.5% | — |
| Return on tangible assets | 2.5% | 12.3% | 14.8% | 16.1% | 24.9% | 43.2% | 59.9% | 42.4% | — |
| Free cash flow margin | 8.7% | 9.2% | 8.6% | 7.0% | 31.2% | 29.2% | 34.4% | 36.7% | 31.7% |
| Income quality (OCF / net income) | 3.74 | 1.09 | 0.78 | 0.94 | 1.82 | 1.01 | 0.86 | 1.71 | 1.90 |
| Financial health | |||||||||
| Total debt | $8.80B | $9.04B | $8.93B | $9.11B | $9.36B | $31.0M | $186.0M | $149.0M | — |
| Cash & short-term investments | $574.0M | $675.0M | $693.0M | $706.0M | $737.0M | $12.0M | $319.0M | $244.0M | — |
| Net debt | $8.23B | $8.36B | $8.24B | $8.41B | $8.63B | $19.0M | −$133.0M | −$95.0M | — |
| Debt / equity | 11.70 | 19.14 | — | — | — | 0.01 | 0.03 | 0.02 | — |
| Debt / assets | 0.68 | 0.69 | 0.74 | 0.83 | 0.88 | 0.00 | 0.02 | 0.01 | — |
| Net debt / EBITDA | 6.38 | 5.21 | 5.74 | 4.79 | 4.35 | 0.01 | −0.03 | −0.02 | — |
| Current ratio | 1.82 | 1.60 | 1.54 | 1.56 | 1.45 | 1.33 | 2.95 | 2.40 | — |
| Quick ratio | 1.23 | 1.11 | 1.09 | 1.17 | 1.10 | 0.99 | 2.15 | 1.76 | — |
| Interest coverage | 2.5 | 2.9 | 2.5 | 4.0 | 7.4 | 474.5 | 641.2 | 60.1 | 155.8 |
| Working capital | $1.96B | $1.63B | $1.59B | $1.42B | $1.16B | $894.0M | $2.61B | $2.17B | — |
| Invested capital | $8.98B | $8.83B | $8.17B | $7.51B | $7.12B | $5.50B | $6.90B | $6.25B | — |
| Tangible asset value | −$4.53B | −$5.62B | −$5.21B | −$6.14B | −$6.76B | $380.0M | $1.86B | $933.0M | — |
| Net current asset value | −$7.76B | −$8.28B | −$7.62B | −$7.92B | −$8.43B | −$1.06B | $442.0M | −$432.0M | — |
| Graham number | $6.82 | $11.69 | — | — | — | $64.41 | $89.16 | $69.28 | — |
| Graham net-net per share | −$37.44 | −$39.26 | −$36.62 | −$36.98 | −$38.89 | −$12.23 | −$5.84 | −$8.73 | — |
| Capital allocation | |||||||||
| Dividends paid | $88.0M | $297.0M | $294.0M | $290.0M | $145.0M | $145.0M | $145.0M | $145.0M | — |
| Share buybacks (net) | — | $22.0M | $17.0M | $11.0M | — | — | — | — | — |
| Dividend payout ratio | 47.1% | 34.4% | 28.7% | 31.6% | 10.7% | 6.7% | 4.5% | 6.7% | — |
| Dividends + buybacks / free cash flow | 16.4% | 54.3% | 57.8% | 69.8% | 7.4% | 7.6% | 5.4% | 4.0% | — |
| Capex / revenue | 2.6% | 5.5% | 4.2% | 6.9% | 7.7% | 4.3% | 1.2% | 1.0% | 0.8% |
| Capex / operating cash flow | 23.1% | 37.4% | 32.7% | 49.8% | 19.9% | 12.7% | 3.3% | 2.7% | 2.5% |
| Capex / depreciation | 0.45 | 1.27 | 1.11 | 2.01 | 2.50 | 1.96 | 0.28 | 0.06 | 0.04 |
| Stock-based compensation / revenue | 1.2% | 1.6% | 1.6% | 1.2% | 0.9% | 0.6% | 0.5% | 0.6% | 0.5% |
| R&D / revenue | 5.9% | 7.3% | 8.4% | 7.6% | 7.0% | 3.2% | 2.8% | 3.7% | 3.4% |
| SG&A / revenue | 27.7% | 27.5% | 30.2% | 27.6% | 22.7% | 20.8% | 18.6% | 20.6% | 21.8% |
| Efficiency | |||||||||
| Days sales outstanding | 85.8 | 95.4 | 100.9 | 92.2 | 84.4 | 83.2 | 74.3 | 59.5 | — |
| Days of inventory on hand | 174.4 | 179.0 | 168.2 | 152.6 | 140.1 | 170.9 | 165.7 | 77.3 | — |
| Days payables outstanding | 134.6 | 167.5 | 177.5 | 200.0 | 125.7 | 44.5 | 43.9 | 22.5 | — |
| Cash conversion cycle (days) | 125.6 | 106.9 | 91.6 | 44.8 | 98.8 | 209.5 | 196.1 | 114.3 | — |
| Receivables turnover | 4.25 | 3.82 | 3.62 | 3.96 | 4.32 | 4.39 | 4.91 | 6.14 | — |
| Payables turnover | 2.71 | 2.18 | 2.06 | 1.82 | 2.90 | 8.20 | 8.31 | 16.24 | — |
| Inventory turnover | 2.09 | 2.04 | 2.17 | 2.39 | 2.61 | 2.14 | 2.20 | 4.72 | — |
| Asset turnover | 0.48 | 0.51 | 0.54 | 0.57 | 0.61 | 0.63 | 0.74 | 0.93 | — |
| Average receivables | $1.46B | $1.67B | $1.73B | $1.56B | $1.46B | $1.49B | $1.58B | $1.59B | — |
| Average payables | $1.05B | $1.23B | $1.22B | $1.26B | $820.5M | $258.5M | $273.5M | $289.0M | — |
| Average inventory | $1.36B | $1.32B | $1.16B | $959.0M | $914.0M | $992.0M | $1.03B | $994.0M | — |
| Intangibles / total assets | 41.1% | 46.5% | 42.6% | 47.9% | 49.2% | 50.5% | 49.0% | 51.6% | — |
Computed from OGN's annual financial statements (latest annual report filed February 24, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
OGN valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Organon traded at 10.0 times earnings, against a 9-year median of 5.7. Based on the latest twelve months, the trailing P/E is 17.6 and the forward P/E is 5.1. Organon earned a return on equity of 30.6% and a return on invested capital of 7.2% in fiscal 2025. It ended the year with $8.8 billion of debt and $574.0 million in cash and short-term investments, net debt of $8.2 billion. It returned $88.0 million to shareholders: $88.0 million in dividends and $0 in share buybacks, 16% of free cash flow. The share count rose 3.0% from 253.1M to 260.8M over 8 years.
See the OGN income statement, the OGN chart for price history, or the OGN stock overview for the latest quote and news.
OGN key metrics FAQ
What is Organon's P/E ratio?
Organon's trailing P/E ratio is 17.6 based on the last twelve months of earnings (as of October 18, 2026), and its forward P/E is 5.1. At the end of fiscal 2025 it was 10.0, compared with a 9-year median of 5.7.
What is Organon's EV/EBITDA?
Organon's enterprise value was 7.8 times EBITDA at the end of fiscal 2025 (enterprise value $10.1 billion, EBITDA $1.3 billion); the current EV/EBITDA is 8.4.
What is Organon's return on equity?
Organon's return on equity (ROE) was 30.6% in fiscal 2025: net income of $187.0 million on average shareholders' equity of $612.0 million.
What is Organon's ROIC?
Organon's return on invested capital was 7.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Organon have?
Organon had total debt of $8.8 billion at the end of fiscal 2025, a debt-to-equity ratio of 11.70 and $8.2 billion of net debt (6.38 times EBITDA).
What is Organon's dividend yield?
Organon's forward dividend yield is 0.58%. Organon paid $88.0 million in dividends in fiscal 2025 ($0.34 per share), a payout ratio of 47.1%.
What is Organon's free cash flow yield?
Organon generated $538.0 million of free cash flow in fiscal 2025, a free cash flow yield of 28.8% on its market value at year-end ($1.9 billion).
What is Organon's current ratio?
Organon's current ratio was 1.82 at the end of fiscal 2025: current assets were 1.82 times current liabilities.